{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:26:14Z","timestamp":1793579174125,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:00:00Z","timestamp":1793577600000},"content-version":"vor","delay-in-days":117,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"European Union\u2019s Horizon 2020 research and innovation programme","award":["Grant number: 643381"],"award-info":[{"award-number":["Grant number: 643381"]}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI135721"],"award-info":[{"award-number":["R01AI135721"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIVI Research Center is supported by The Novo Nordisk Foundation","award":["Grant number: NNF23SA0088562"],"award-info":[{"award-number":["Grant number: NNF23SA0088562"]}],"id":[{"id":"https:\/\/ror.org\/04txyc737","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-026-01509-6","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:05:47Z","timestamp":1783469147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Post-exposure vaccination with an adjuvanted protein subunit vaccine, but not BCG, protects mice and guinea pigs against M. tuberculosis"],"prefix":"10.1038","volume":"11","author":[{"given":"Joshua S.","family":"Woodworth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Aagaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Salguero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lindenstr\u00f8m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus","family":"Mortensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"1509_CR1","unstructured":"(WHO), W. H. O. Global Tuberculosis Report 2024. (World Health Organization, 2024)."},{"key":"1509_CR2","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.3390\/pathogens11111228","volume":"11","author":"M Coleman","year":"2022","unstructured":"Coleman, M., Martinez, L., Theron, G., Wood, R. & Marais, B. Mycobacterium tuberculosis transmission in high-incidence settings-new paradigms and insights. Pathogens 11, 1228 (2022).","journal-title":"Pathogens"},{"key":"1509_CR3","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1080\/21645515.2016.1205769","volume":"12","author":"RC Harris","year":"2016","unstructured":"Harris, R. C., Sumner, T., Knight, G. M. & White, R. G. Systematic review of mathematical models exploring the epidemiological impact of future TB vaccines. Hum. Vaccines Immunother. 12, 2813\u20132832 (2016).","journal-title":"Hum. Vaccines Immunother."},{"key":"1509_CR4","doi-asserted-by":"crossref","unstructured":"Mangtani, P. et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin. Infect. Dis. 58, 470\u2013480 (2014).","DOI":"10.1093\/cid\/cit790"},{"key":"1509_CR5","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa2412381","volume":"392","author":"AC Schmidt","year":"2025","unstructured":"Schmidt, A. C. et al. BCG revaccination for the prevention of mycobacterium tuberculosis infection. N. Engl. J. Med. 392, 1789\u20131800 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1509_CR6","doi-asserted-by":"publisher","unstructured":"Abubakar, I. et al. Systematic review and meta-analysis of the current evidence on the duration of protection by Bacillus Calmette-Gu\u00e9rin vaccination against tuberculosis. Health Technol. Assess. 17, https:\/\/doi.org\/10.3310\/hta17370 (2013).","DOI":"10.3310\/hta17370"},{"key":"1509_CR7","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/S0140-6736(05)67145-0","volume":"366","author":"LC Rodrigues","year":"2005","unstructured":"Rodrigues, L. C. et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet 366, 1290\u20131295 (2005).","journal-title":"Lancet"},{"key":"1509_CR8","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/S1473-3099(23)00818-6","volume":"24","author":"PCP dos Santos","year":"2024","unstructured":"dos Santos, P. C. P. et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in adult Brazilian health-care workers: a nested clinical trial. Lancet Infect. Dis. 24, 594\u2013601 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"1509_CR9","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1084\/jem.104.5.763","volume":"104","author":"RM McCune Jr.","year":"1956","unstructured":"McCune, R. M. Jr., McDermott, W. & Tompsett, R. The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J. Exp. Med. 104, 763\u2013802 (1956).","journal-title":"J. Exp. Med."},{"key":"1509_CR10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tube.2012.02.008","volume":"92","author":"M Henao-Tamayo","year":"2012","unstructured":"Henao-Tamayo, M. et al. A mouse model of tuberculosis reinfection. Tuberculosis 92, 211\u2013217 (2012).","journal-title":"Tuberculosis"},{"key":"1509_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ebiom.2017.12.004","volume":"27","author":"T Lindenstr\u00f8m","year":"2018","unstructured":"Lindenstr\u00f8m, T. et al. T Cells Primed by Live Mycobacteria Versus a Tuberculosis Subunit Vaccine Exhibit Distinct Functional Properties. EBioMedicine 27, 27\u201339 (2018).","journal-title":"EBioMedicine"},{"key":"1509_CR12","doi-asserted-by":"publisher","first-page":"e0002077","DOI":"10.1371\/journal.pgph.0002077","volume":"3","author":"M Amofa-Sekyi","year":"2023","unstructured":"Amofa-Sekyi, M. et al. Prevalence and risk factors of M tuberculosis infection in young people across 14 communities in Zambia and South Africa. PLOS Glob. Public Health 3, e0002077 (2023).","journal-title":"PLOS Glob. Public Health"},{"key":"1509_CR13","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1084\/jem.20100265","volume":"207","author":"A Cruz","year":"2010","unstructured":"Cruz, A. et al. Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. J. Exp. Med. 207, 1609\u20131616 (2010).","journal-title":"J. Exp. Med."},{"key":"1509_CR14","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/S1473-3099(24)00814-4","volume":"25","author":"\u00c1 Borges","year":"2025","unstructured":"Borges, \u00c1. et al. Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Infect. Dis. 25, 751\u2013763 (2025).","journal-title":"Lancet Infect. Dis."},{"key":"1509_CR15","first-page":"239","volume":"215","author":"GA Rook","year":"1996","unstructured":"Rook, G. A. & Stanford, J. L. The Koch phenomenon and the immunopathology of tuberculosis. Curr. Top. Microbiol. Immunol. 215, 239\u2013262 (1996).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"1509_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26934-0","volume":"12","author":"JS Woodworth","year":"2021","unstructured":"Woodworth, J. S. et al. A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Gu\u00e9rin. Nat. Commun. 12, 6658 (2021).","journal-title":"Nat. Commun."},{"key":"1509_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00666-2","volume":"8","author":"K Dijkman","year":"2023","unstructured":"Dijkman, K. et al. A protective, single-visit TB vaccination regimen by co-administration of a subunit vaccine with BCG. NPJ Vaccines 8, 66 (2023).","journal-title":"NPJ Vaccines"},{"key":"1509_CR18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nm.2285","volume":"17","author":"C Aagaard","year":"2011","unstructured":"Aagaard, C. et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat. Med. 17, 189\u2013194 (2011).","journal-title":"Nat. Med."},{"key":"1509_CR19","doi-asserted-by":"publisher","first-page":"e0196815","DOI":"10.1371\/journal.pone.0196815","volume":"13","author":"S Leung-Theung-Long","year":"2018","unstructured":"Leung-Theung-Long, S. et al. A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis. PLoS ONE 13, e0196815 (2018).","journal-title":"PLoS ONE"},{"key":"1509_CR20","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.micinf.2016.03.005","volume":"18","author":"M Gengenbacher","year":"2016","unstructured":"Gengenbacher, M., Kaiser, P., Schuerer, S., Lazar, D. & Kaufmann, S. H. Post-exposure vaccination with the vaccine candidate Bacillus Calmette-Gu\u00e9rin \u0394ureC::hly induces superior protection in a mouse model of subclinical tuberculosis. Microbes Infect. 18, 364\u2013368 (2016).","journal-title":"Microbes Infect."},{"key":"1509_CR21","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1093\/infdis\/jiv503","volume":"213","author":"N Aguilo","year":"2015","unstructured":"Aguilo, N. et al. Pulmonary but not subcutaneous delivery of BCG vaccine confers protection to tuberculosis-susceptible mice by an interleukin 17\u2013dependent mechanism. J. Infect. Dis. 213, 831\u2013839 (2015).","journal-title":"J. Infect. Dis."},{"key":"1509_CR22","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1093\/infdis\/jis425","volume":"207","author":"RN Coler","year":"2013","unstructured":"Coler, R. N. et al. Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment. J. Infect. Dis. 207, 1242\u20131252 (2013).","journal-title":"J. Infect. Dis."},{"key":"1509_CR23","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.4049\/jimmunol.1101122","volume":"187","author":"CL Day","year":"2011","unstructured":"Day, C. L. et al. Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J. Immunol. 187, 2222\u20132232 (2011).","journal-title":"J. Immunol."},{"key":"1509_CR24","doi-asserted-by":"publisher","first-page":"e142014","DOI":"10.1172\/JCI142014","volume":"131","author":"P Ogongo","year":"2021","unstructured":"Ogongo, P. et al. Tissue-resident-like CD4+ T cells secreting IL-17 control Mycobacterium tuberculosis in the human lung. J. Clin. Investig. 131, e142014 (2021).","journal-title":"J. Clin. Investig."},{"key":"1509_CR25","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.3389\/fimmu.2017.01973","volume":"8","author":"R Billeskov","year":"2017","unstructured":"Billeskov, R. et al. High antigen dose is detrimental to post-exposure vaccine protection against tuberculosis. Front. Immunol. 8, 1973 (2017).","journal-title":"Front. Immunol."},{"key":"1509_CR26","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.cell.2006.02.013","volume":"124","author":"D Young","year":"2006","unstructured":"Young, D. & Dye, C. The development and impact of tuberculosis vaccines. Cell 124, 683\u2013687 (2006).","journal-title":"Cell"},{"key":"1509_CR27","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1128\/IAI.68.3.1706-1709.2000","volume":"68","author":"J Turner","year":"2000","unstructured":"Turner, J. et al. Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode. Infect. Immun. 68, 1706\u20131709 (2000).","journal-title":"Infect. Immun."},{"key":"1509_CR28","unstructured":"Organization, W. H. WHO Preferred Product Characteristics for New Tuberculosis Vaccines (World Health Organization, 2018)."},{"key":"1509_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.585359","volume":"11","author":"HS Clemmensen","year":"2020","unstructured":"Clemmensen, H. S. et al. Rescuing ESAT-6 specific CD4 T cells from terminal differentiation is critical for long-term control of murine Mtb infection. Front. Immunol. 11, 585359 (2020).","journal-title":"Front. Immunol."},{"key":"1509_CR30","doi-asserted-by":"publisher","first-page":"e082916","DOI":"10.1136\/bmjopen-2023-082916","volume":"14","author":"M Singh","year":"2024","unstructured":"Singh, M. et al. PreVenTB trial: protocol for evaluation of efficacy and safety of two vaccines VPM1002 and Immuvac (Mw) in preventing tuberculosis (TB) in healthy household contacts of newly diagnosed sputum smear-positive pulmonary TB patients: phase III, randomised, double-blind, three-arm placebo-controlled trial. BMJ Open 14, e082916 (2024).","journal-title":"BMJ Open"},{"key":"1509_CR31","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","volume":"381","author":"DR Tait","year":"2019","unstructured":"Tait, D. R. et al. Final analysis of a trial of M72\/AS01(E) vaccine to prevent tuberculosis. N. Engl. J. Med. 381, 2429\u20132439 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1509_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-03514-1","volume":"7","author":"SK Sharma","year":"2017","unstructured":"Sharma, S. K. et al. Efficacy and safety of mycobacterium indicus pranii as an adjunct therapy in category II pulmonary tuberculosis in a randomized trial. Sci. Rep. 7, 3354 (2017).","journal-title":"Sci. Rep."},{"key":"1509_CR33","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/ni1449","volume":"8","author":"SA Khader","year":"2007","unstructured":"Khader, S. A. et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat. Immunol. 8, 369\u2013377 (2007).","journal-title":"Nat. Immunol."},{"key":"1509_CR34","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3390\/vaccines12020128","volume":"12","author":"EL Stewart","year":"2024","unstructured":"Stewart, E. L. et al. Lung IL-17A-producing CD4+ T cells correlate with protection after intrapulmonary vaccination with differentially adjuvanted tuberculosis vaccines. Vaccines 12, 128 (2024).","journal-title":"Vaccines"},{"key":"1509_CR35","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41591-018-0319-9","volume":"25","author":"K Dijkman","year":"2019","unstructured":"Dijkman, K. et al. Prevention of tuberculosis infection and disease by local BCG in repeatedly exposed rhesus macaques. Nat. Med. 25, 255\u2013262 (2019).","journal-title":"Nat. Med."},{"key":"1509_CR36","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.celrep.2018.04.003","volume":"23","author":"E Van Dis","year":"2018","unstructured":"Van Dis, E. et al. STING-activating adjuvants elicit a Th17 immune response and protect against mycobacterium tuberculosis infection. Cell Rep. 23, 1435\u20131447 (2018).","journal-title":"Cell Rep."},{"key":"1509_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00897-x","volume":"9","author":"V Rungelrath","year":"2024","unstructured":"Rungelrath, V. et al. Vaccination with Mincle agonist UM-1098 and mycobacterial antigens induces protective Th1 and Th17 responses. NPJ Vaccines 9, 100 (2024).","journal-title":"NPJ Vaccines"},{"key":"1509_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-99651-9","volume":"11","author":"LHW Lau","year":"2021","unstructured":"Lau, L. H. W. et al. Seasonality of tuberculosis in intermediate endemicity setting dominated by reactivation diseases in Hong Kong. Sci. Rep. 11, 20259 (2021).","journal-title":"Sci. Rep."},{"key":"1509_CR39","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1128\/IAI.02086-05","volume":"74","author":"S Hervas-Stubbs","year":"2006","unstructured":"Hervas-Stubbs, S. et al. High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection. Infect. Immun. 74, 3396\u20133407 (2006).","journal-title":"Infect. Immun."},{"key":"1509_CR40","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1016\/j.vaccine.2015.03.083","volume":"33","author":"D Bottai","year":"2015","unstructured":"Bottai, D. et al. Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system. Vaccine 33, 2710\u20132718 (2015).","journal-title":"Vaccine"},{"key":"1509_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2023.1264200","volume":"10","author":"F Larenas-Mu\u00f1oz","year":"2023","unstructured":"Larenas-Mu\u00f1oz, F. et al. Characterisation and development of histopathological lesions in a guinea pig model of Mycobacterium tuberculosis infection. Front. Vet. Sci. 10, 1264200 (2023).","journal-title":"Front. Vet. Sci."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01509-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01509-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01509-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T23:26:41Z","timestamp":1793575601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01509-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1509"],"URL":"https:\/\/doi.org\/10.1038\/s41541-026-01509-6","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"19 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.M. and C.A. are co-inventors of a patent covering the use of H107 and derivatives. R.M. and J.S.W. are co-inventors of a patent covering the use of the related adjuvant CAF\u00ae10b. All rights have been assigned to Statens Serum Institut. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"202"}}